Stratrix
On the Record · Dexcom

Dexcom acquisitions, on the record

The businesses Dexcom bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
non-diabetes distribution business
Word for word“The change in goodwill for the twelve months ended December 31, 2024 and 2023 primarily consisted of the divestiture of our non-diabetes distribution business and translation adjustments on our foreign currency denominated goodwill.” 10-K for 2024
divestiture——
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)
2016-12-31−$300,000
2017-12-31$0
2018-12-31$11.3 million
2019-12-31$0
2020-12-31$0
2021-12-31$30.2 million
2022-12-31$3.9 million
2023-12-31$0
2024-12-31$0

Deal filings since 2016

Read from Dexcom’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.